Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

No longer available × osimertinib × Thoracic × Clear all

Status

Active not recruiting 52 Recruiting 45 Completed 42 Unknown 33 Not yet recruiting 21 Terminated 10 Withdrawn 1 Suspended 1 No longer available 1

Sponsor Class

Study Type

Expanded_access 1

Sponsor

Cancer Type

Conditions

EGFR T790M Mutation Positive NSCLC 1

Interventions

tazemetostat 1 taletrectinib 1 rovalpituzumab tesirine 1 rociletinib 1 pegilodecakin 1 patritumab deruxtecan 1 osimertinib 1 lorlatinib 1 dabrafenib 1 ceritinib 1 capmatinib 1 brigatinib 1 alectinib 1 Suspensions 1 Powders 1 Paclitaxel 1 Nivolumab 1 BID protein, human 1 AM0010 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02451852 2016-07-14

AZD9291 US Expanded Access Program

AstraZeneca

No longer available

EGFR T790M Mutation Positive NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡